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Recent studies have uncovered various pleiotrophic effects of
3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibiting
drugs (statins). Several studies have identified a beneficial
effect of statins on diabetic nephropathy; however, the
molecular mechanisms are unclear. In this study, we show
that statin ameliorates nephropathy in db/db mice, a rodent
model of type 2 diabetes, via downregulation of NAD(P)H
oxidase NOX4, which is a major source of oxidative stress in
the kidney. Pitavastatin treatment for 2 weeks starting
at 12 weeks of age significantly reduced albuminuria in the
db/db mice concomitant with a reduction of urinary
8-hydroxy-20-deoxyguanosine and 8-epi-prostaglandin F2a.
Immunohistochemical analysis found increased amounts of
8-hydroxy-20-deoxyguanosine and NOX4 protein in the
kidney of db/db mice. Quantitative reverse transcription-
polymerase chain reaction also showed increased levels of
NOX4 mRNA. Pitavastatin normalized all of these changes in
the kidneys of diabetic animals. Additionally, 12-week
treatment with the statin completely normalized the levels of
transforming growth factor-b1 and fibronectin mRNA as well
as the mesangial expansion characteristic of diabetic
nephropathy. Our study demonstrates that pitavastatin
ameliorates diabetic nephropathy in db/db mice by
minimizing oxidative stress by downregulating NOX4
expression. These findings may provide insight into the
mechanisms of statin therapy in early stages of diabetic
nephropathy.
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Diabetic nephropathy is a leading cause of end-stage renal
disease worldwide. Establishment of therapeutic strategies
targeted at the causative mechanisms of diabetic nephropathy
has become increasingly urgent. In recent years, oxidative
stress has emerged as an important pathogenic factor in the
development of diabetic vascular complications, including
nephropathy.1–5 Accumulating evidence has shown that many
protein, lipid, and DNA markers of oxidative stress are
increased in vascular tissues and kidney from animals and
from patients with diabetes.4–6 Although multiple pathways
may be involved in the generation of reactive oxygen species
(ROS),7–9 we and other investigators have shown that
nonphagocytic NAD(P)H oxidases may be a major source
of increased ROS production in vascular tissues in
diabetes.10–15 The phagocytic NAD(P)H oxidase comprises
two plasma membrane-associated proteins, gp91phox
(NOX2) and p22phox, and several cytosolic regulatory
subunits, p47phox, p67 phox, p40phox, and small GTP-
binding protein Rac1 or Rac2. Nonphagocytic NAD(P)H
oxidases are isoforms of the phagocytic oxidase. In the
kidney, the catalytic subunit gp91phox is replaced with a
homolog of gp91phox termed NOX4. Human NOX4 exhibits
39% identity with human gp91phox, with several conserva-
tions in membrane-spanning regions and binding sites for
heme, flavin adenine dinucleotide, and NAD(P)H, indicative
of its function as a superoxide-producing NAD(P)H
oxidase.16–18 It has been implicated that NOX4, as a major
source of ROS production in the kidney, could have a role
under pathological conditions.19,20 We previously reported
that increased expression of NOX4 might play an important
role in increased ROS production in the kidney of
streptozotocin-induced diabetic rats.21 This notion was
supported by a recent report showing that downregulation
of NOX4 induced by antisense oligonucleotides completely
attenuated oxidative stress in the kidneys of streptozotocin-
induced diabetic rats concomitant with the normalization of
renal hypertrophy and increased fibronectin expression.19
Thus, NAD(P)H oxidase NOX4 might be a therapeutic target
for attenuating ROS production in the kidney and preventing
the development of diabetic nephropathy.
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3-Hydroxy-3-methylglutaryl coenzyme A reductase inhi-
bitors (statins) are widely used as cholesterol-lowering
agents. Accumulating evidence has revealed that they have
anti-inflammatory and antioxidative actions that are inde-
pendent of their cholesterol-lowering effect.22–25 Recently,
several reports have suggested that statins may have a
beneficial effect on diabetic nephropathy through these
pleiotropic actions.26–28 Usui H et al.27 reported that
cerivastatin ameliorated nephropathy in streptozotocin-
induced diabetic rats through its anti-inflammatory action.
However, the precise molecular mechanisms remain unclear.
Notably, statins have been reported to inhibit superoxide
production in vascular cells via inhibition of angiotensin
II-induced NAD(P)H oxidase activation.29–31 In addition,
we reported that pitavastatin attenuated high glucose-
induced and diabetes-induced oxidative stress in vitro and
in vivo evaluated by electron spin resonance measurements,
which was mediated by inhibition of NAD(P)H oxidase
activity.32
In this study, we investigated whether statin treatment
ameliorates nephropathy in db/db mice, a rodent model of
type 2 diabetes. In addition, to explore the underlying
molecular mechanisms, the effect of statin on the expression
of NAD(P)H oxidase NOX4, which may be a major source of
ROS production in the kidney, was examined.
RESULTS
Metabolic data
The body weights and blood glucose levels of db/db and
db/þ mice are summarized in Table 1. At baseline (12 weeks
of age), both body weight and blood glucose level were
significantly higher in db/db mice than in db/þ mice. Two
weeks after the start of treatment, pitavastatin had not
significantly affected body weights or blood glucose level in
db/db or db/þ mice. As shown in Table 2, pitavastatin also
did not significantly affect serum levels of total cholesterol,
triglyceride, or high-density lipoprotein-cholesterol in the
db/db and db/þ mice.
Urinary albumin excretion
Urinary albumin excretion was significantly higher in
nontreated db/db mice than in nontreated db/þ mice at
14 weeks of age (242.4750.3 vs 22.872.3 mg/day, Po0.01).
Pitavastatin treatment significantly reduced urinary albumin
excretion in db/db mice. (242.4750.3 vs 56.974.1 mg/day,
Po0.01) (Figure 1).
Table 1 | Body weights and blood glucose levels in db/+ and db/db mice at baseline and at 2 weeks after treatment
Body weight (g) Blood glucose levels (mg/dl)
n Baseline After treatment Baseline After treatment
db/+ 8 28.870.4
i
# 27.070.2
i
# 138.377.9
i
# 134.575.1
i
#
db/+plus pitavastatin 8 27.670.5 28.570.4 129.674.9 118.975.6
db/db 8 47.570.6*
i
# 48.470.9*
i
# 392.5711.1*
i
# 376.9711.7*
i
#
db/db plus pitavastatin 8 45.670.5** 46.471.0** 409.0711.6** 396.3719.1**
*Po0.01 vs nontreated db/+, **Po0.01 vs treated db/+, #, not significant, data are mean7s.e.
Table 2 | Serum TC, TG, and HDL-cholesterol concentration in db/+ and db/db mice at 2 weeks after treatment
TC (mg/dl) TG (mg/dl) HDL-C (mg/dl)
db/+ 62.473.7
i
#
64.376.0
i
#
42.279.8
i
#
db/+plus pitavastatin 82.373.0 62.378.8 45.676.5
db/db 149.5710.3*
i
#
99.478.6*
i
#
46.679.4
i
#
db/db plus pitavastatin 147.5711.1** 83.878.9** 46.875.3
TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein.
*Po0.01 vs nontreated db/+, **Po0.01 vs treated db/+, #, not significant, data are mean7s.e.
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Figure 1 | Effect of pitavastatin treatment on urinary albumin
excretion (lg/day). Pitavastatin was given orally to db/db (n¼ 8)
and db/þ (n¼ 8) mice (5 mg/kg) once daily for 2 weeks. The other
half of the db/db and db/þ mice were given the same volume of
solution without pitavastatin. The albumin concentration was
analyzed as described in the Materials And Methods. P, nontreated
group; Pþ , pitavastatin-treated group. Results are expressed as the
mean7s.e. *Po0.05; **Po0.01; #not significant.
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Urinary 8-OHdG and 8-epi-PGF2a
Urinary 8-OHdG excretion and 8-epi-PGF2a excretion were
significantly higher in nontreated db/db mice than in
nontreated db/þ mice at 14 weeks of age (133.2726. 7 vs
74.8713.5 ng/day, Po0.05; 175.4719.0 vs 39.473.9 ng/day,
Po0.001, respectively). Pitavastatin treatment reduced both
urinary 8-OHdG excretion and urinary 8-epi-PGF2a excre-
tion in db/db mice to the control level (Figure 2).
Immunostaining analysis of 8-OHdG
We next evaluated oxidative stress in renal tissue by
immunostaning analysis of 8-OHdG. The staining intensities
of 8-OHdG in the db/db mice were apparently stronger in
both renal tubules and to a lesser extent in the glomeruli than
those in db/þ mice. Positive 8-OHdG stain was increased
mainly in the cytosol and to a lesser extent in the nuclei of
the renal cells of db/db mice. Pitavastatin treatment restored
the intensity of 8-OHdG staining in db/db mice to the
control level (Figure 3).
Immunostaining analysis of NOX4
Positive staining of NOX4 was observed in the renal tubules
and faint staining was detected in the glomeruli of nontreated
db/þ mice at 14 weeks of age. In the kidneys of nontreated
db/db mice, the staining intensities of NOX4 protein were
apparently stronger in both renal tubules and the glomeruli
than those in db/þ mice (Figure 4). The localization and
staining intensities of NOX4 were in accordance with those of
8-OHdG staining. Pitavastatin treatment restored the inten-
sity of NOX4 staining to the control level in both the tubules
and the glomeruli, in parallel with the changes of
8-OHdG staining (Figure 4).
NOX4 mRNA expression
NOX4 mRNA levels were quantified by real-time reverse
trancription-polymerase chain reaction (RT-PCR). They were
significantly increased in both the cortices and the medullae
of nontreated db/db mice (315.77143.6%, Po0.01;
212.6743.0%, Po0.01; respectively) compared with non-
treated db/þ mice. Consistent with the immunostaining
analysis, pitavastatin treatment normalized NOX4 mRNA in
db/db mice to the control level in both the cortices and the
medullae (146.1769.2%, not significant (NS) vs control;
122.9760.0%, NS vs control; respectively) (Figure 5).
Suppression of mesangial expansion
To investigate the effect of pitavastatin treatment on
mesangial expansion, which is one of the most striking
characteristics of diabetic nephropathy, pitavastatin was given
orally (5 mg/kg/day) for 12 weeks starting at 12 weeks of
age. The glomerular structure in db/db mice showed
accelerated mesangial expansion characterized by an increase
in periodic acid-Sciff (PAS)-positive mesangial matrix area
compared with that observed in db/þ mice at 24 weeks of
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Figure 2 | Effect of pitavastatin treatment on (a) urinary 8-OHdG
excretion (ng/day) and (b) urinary 8-epi-PGF2a excretion
(ng/day). 8-OHdG and 8-epi-PGF2a concentrations were measured as
described in the Materials and Methods. P, nontreated group;
Pþ , pitavastatin-treated group. Results are expressed as the
mean7s.e. *Po0.05; **Po0.01; ***Po0.001; #not significant.
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Figure 3 | Effects of pitavastatin treatment on 8-OHdG levels
in renal tissues. After 2 weeks of treatment, 8-OHdG levels were
evaluated by immunostaining of renal tissues from (a and e)
nontreated controls, (b and f) pitavastatin-treated controls,
(c and g) nontreated diabetic, and (d and h) pitavastatin-treated
diabetic mice. The pictures are representative of the samples from
eight control mice, eight pitavastatin-treated control mice, eight
nontreated diabetic mice, and eight pitavastatin-treated diabetic
mice. Similar results were obtained in all samples from the kidneys
of each group.
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age (Figure 6a–d). Mesangial expansion was semiquantified
by measuring the PAS-positive mesangial matrix area as
described in the Materials and Methods. The PAS-positive
and nuclei-free mesangial area was markedly increased in the
glomeruli of nontreated db/db mice (342.5798.6%,
Po0.001). Pitavastatin treatment prevented mesangial ex-
pansion in db/db mice, which were not significantly different
from the controls (128.5743.3%, NS vs control) (Figure 6e).
In addition, the levels of transforming growth factor b1
(TGF-b1) and fibronectin mRNA were significantly increased
in both cortices and medullae of db/db mice (TGF-b1:
669.67113.9%, Po0.001, 262.0777.0%, Po0.01, respec-
tively; fibronectin: 329.6759.0%, Po0.001, 252.5752.6%,
Po0.001, respectively) compared with control mice. Pita-
vastatin treatment normalized both levels of TGF-b1 and
fibronectin mRNA in db/db mice to the control level
(Figure 7).
DISCUSSION
In this study, we showed that pitavastatin treatment
ameliorated albuminuria concomitantly with a reduction of
urinary and renal tissue oxidative stress markers. In addition,
its long-term treatment also normalized the increased
expression of TGF-b1 and fibronection, and normalized a
renal mesangial expansion, which is one of the most striking
morphologic characteristics of diabetic nephropathy in db/db
mice, a rodent model of type 2 diabetes. Furthermore, this
study showed for the first time that the underlying
mechanism of these beneficial effects may be mediated by
downregulation of NAD(P)H oxidase NOX4 expression.
Either antioxidant supplementation such as vitamin E or
lipoic acid, or overexpression of superoxide dismutase has
been reported to attenuate renal injury in experimental
models of diabetes.33–35 These findings support an important
role for oxidative stress in the pathogenesis of diabetic
nephropathy. However, the precise molecular mechanism for
increased oxidative stress in diabetic kidneys remained to be
elucidated. The NAD(P)H oxidase isoform NOX4 was cloned
from the kidney and found to be highly expressed there.16–18
It has been suggested that NOX4, as a major source of ROS
production in the kidney, could have a role under
pathological conditions. Although the nature of the sources
of ROS overproduction in diabetes is not precisely defined,
we and other investigators have suggested that nonphagocytic
NAD(P)H oxidases may be major sources in vascular tissues
in diabetes.10–15 We previously reported that, in the kidneys
of streptozotocin-induced diabetic rats, increased expression
of NOX4 might play an important role in increased ROS
production.21 Gorin et al.19 also reported increased expres-
sion of NOX4 in the diabetic kidney, and further showed that
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Figure 4 | Effects of pitavastatin treatment on NOX4 expression.
After 2 weeks of treatment, NOX4 protein levels were evaluated by
immunostaining of renal tissues from (a and e) nontreated control,
(b and f) pitavastatin-treated control, (c and g) nontreated diabetic,
and (d and h) pitavastatin-treated diabetic mice. The pictures are
representative of the samples from eight control mice, eight
pitavastatin-treated control mice, eight nontreated diabetic mice,
and eight pitavastatin-treated diabetic mice. Similar results were
obtained in all samples from the kidneys of each group.
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Figure 5 | Effect of pitavastatin on NOX4 mRNA expression in the
renal cortices and renal medullae from nontreated control,
pitavastatin-treated control, nontreated diabetic, and
pitavastatin-treated diabetic mice. After 2 weeks of treatment,
total RNA was extracted from the kidneys of each group of mice.
NOX4 mRNA expression levels were measured by competitive RT-PCR
analysis. mRNA expression was normalized to the level of b-actin
and the results are expressed as the mean percentage of the
level in nontreated controls7s.e. P, nontreated group;
Pþ , pitavastatin-treated group. *Po0.01; **Po0.001; #not
significant.
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downregulation of NOX4 induced by antisense oligonucleo-
tides completely attenuated oxidative stress in the kidneys of
streptozotocin-induced diabetic rats. This is in agreement
with the present finding that downregulation of NOX4
induced by pitavastatin completely attenuated oxidative
stress in the kidneys of db/db mice. Taken together, these
results suggest a role for NOX4 as the major source of ROS
production in the diabetic kidney.
We previously reported that high glucose levels stimulate
superoxide production via protein kinase C-dependent
activation of NAD(P)H oxidases in cultured aortic endothe-
lial cells and smooth muscle cells.10 The mechanism under-
lying protein kinase C-dependent activation of NAD(P)H
oxidase was supposed to be protein kinase C-dependent
activation of small GTPase Rac-1, which is an important
regulator of NAD(P)H oxidase activation.32 Stains inhibit the
synthesis of various isoprenoids such as farnesyl pyropho-
sphate and geranylgeranyl pyrophosphate in addition to
inhibiting the synthesis of cholesterol.36 Farnesyl pyropho-
sphate and geranylgeranyl pyrophosphate are important
attachments for the post-translational modification of small
GTPases such as Rho and Rac.37 The pleiotropic effects are
supposed to be at least partly mediated by small GTPases.
Indeed, we found that pitavastatin attenuated high glucose-
induced superoxide production in vascular cells by inhibiting
NAD(P)H oxidases, which was mediated by inhibition of
Rac-1.32 However, recent studies have suggested that NOX4
functions independent of the presence of cytosolic regulatory
subunits, including Rac, in contrast to other isoforms of
NAD(P)H oxidase.38 NOX4 activity may depend on its own
expression. In this respect, the molecular mechanism of the
effect of pitavastatin on NOX4 expression remains unclear
and should be clarified in further studies. Although the
detailed mechanism of the regulation of NOX4 expression is
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Figure 6 | Effect of long-term treatment with pitavastatin on
mesangial expansion. After 12 weeks of treatment (5 mg/kg/day),
renal sections were stained with PAS. The extent of increase in the
mesangial matrix was determined by the presence of PAS-positive
and nuclei-free areas in the mesangium. The pictures are
representative of the samples from (a) eight nontreated control mice,
(b) eight pitavastatin-treated control mice, (c) eight nontreated
diabetic mice, and (d) eight pitavastatin-treated diabetic mice.
Semiquantitative analysis of mesangial area is shown in (e) the lower
panel. Mesangial area was determined as described in the
Materials and Methods. Results are expressed as the mean
percentage in nontreated controls7s.e. P, nontreated group;
Pþ , pitavastatin-treated group. *Po0.001; #not significant.
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Figure 7 | Effect of long-term treatment with pitavastatin on the
expression of (a) TGF-b1 mRNA and (b) fibronectin mRNA in renal
cortices and medullae. After 12 weeks of treatment, total RNA was
extracted from the kidneys of each group. The expression levels of
TGF-b1 mRNA and fibronectin mRNA were measured by competitive
RT-PCR analysis. Expression level of mRNA was normalized to the
level of b-actin and the results were expressed as the mean
percentage of the level in nontreated controls7s.e. P, nontreated
group; Pþ , pitavastatin-treated group. *Po0.05; **Po0.01;
***Po0.001; #not significant.
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unknown, it is speculated that high glucose levels and
angiotensin II might be involved in the increased expression
of NOX4 in the diabetic kidney. Previous reports showed that
angiotensin II induces protein synthesis and hypertrophy via
NOX4-derived ROS in renal mesangial cells.39,40 We also
reported that angiotensin II type 1 receptor blocker normali-
zed oxidative stress concomitant with downregulation of
NOX4 expression in streptozotocin-induced diabetic mice.41
High glucose levels or diabetes may enhance the local renin-
angiotensin system in the diabetic kidney, and increased
angiotensin II might induce NOX4 expression.
A previous report showed that NOX4-derived ROS-
mediated kidney hypertrophy and fibronectin expression.19
This is in agreement with our findings that pitavastatin
ameliorated renal mesangial expansion concomitant with a
reduction of oxidative stress that is mediated by the
downregulation of NOX4 expression. However, immuno-
staining analysis showed that NOX4 expression and 8-OHdG
were abundant in renal tubules as well as in glomeruli. It has
been suggested that the rate of functional deterioration
correlates with the degree of tubulointerstitial fibrosis in
diabetic nephropathy. It is tempting to speculate that NOX4-
derived ROS may contribute to tubulointerstial injury as well
as glomerular lesions in the diabetic kidney. This notion is
supported by the previous finding that pitavastatin reduced
L-FABP, which is a marker of tubulointerstitial injury,
concomitant with a reduction of urinary 8-OHdG in patients
with early diabetic nephropathy.42 The relationship between
NOX4 and tubulointerstitial injury and the effect of statins
on it should be clarified in future studies.
In conclusion, we showed for the first time that
pitavastatin ameliorated diabetic nephropathy via inhibition
of oxidative stress mediated by downregulation of NOX4
expression in a rodent model of type 2 diabetes. These
findings may provide a new insight into the efficacy of statin
therapy in the early stage of diabetic nephropathy.
MATERIALS AND METHODS
Animals
Male C57BL/KsJ db/db mice and their age-matched lean littermates,
db/þ mice, were purchased from Clea Japan Inc. (Tokyo, Japan).
All mice were bred under pathogen-free conditions at Kyusyu
University Animal Center (Fukuoka, Japan). The animals had free
access to tap water and standard chow (Clea Japan Inc., Tokyo,
Japan) containing 50.1 carbohydrates, 25.1 proteins, 7.1 minerals,
4.5 fat, and 4.3% cellulose. At 12 weeks of age, half of the db/db and
db/þ mice were randomly chosen to receive pitavastatin (kindly
provided by Kowa Pharmaceutical Co. Ltd, Tokyo, Japan).
Pitavastatin was dissolved in 0.5% carboxymethylcellulose-Na
solution and orally given to the db/db (n¼ 8) and db/þ (n¼ 8)
mice (5 mg/kg) once daily for 2 weeks. The other half of the db/db
and db/þ mice were given the same volume of 0.5% carbox-
ymethylcellulose-Na solution without pitavastatin. After 2 weeks of
treatment, blood samples were obtained from the retro-orbital
venous plexus for determination of the plasma concentration of
total cholesterol, high-density lipoprotein-cholesterol, and triglycer-
ide. A 24-h urine sample was collected using metabolic cages (one
mouse per cage) for the last 3 days of the 2-week treatment. The
well-mixed urine was centrifuged at 7500 g for 5 min, purged of air
with a steam of nitrogen to prevent artificial formation of 8-hydroxy-
20-deoxyguanosine (8-OHdG), and then stored at 801C until
analysis. After these procedures, all mice were anesthetized with
pentobarbital (0.1 mg/g intraperitoneally) and killed. Both kidneys
were rapidly dissected and separated into cortices and medullae for
the following experiments. The samples were frozen in liquid nitrogen
and kept at 801C until use. All protocols were reviewed and
approved by the Committee on the Ethics of Animal Experiments,
Graduate School of Medical Science, Kyusyu University.
Blood and urine analysis
Plasma concentrations of total cholesterol, high-density lipoprotein-
cholesterol, and triglyceride were measured using a commercially
available kit (KAINOS Laboratories Inc., Tokyo, Japan). Urinary
albumin concentrations were measured using a Mouse Albumin
ELISA Kit (AKRAL-121; Shibayagi, Gunma, Japan). The detection
range was 501000 ng/ml. Urinary albumin excretion was expressed
as the total amount excreted in 24 h. After proper dilution,
urine 8-OHdG concentrations were measured using a competitive
enzyme-linked immunosorbent assay kit (8OHdG Check;
Japan Institute for the Control of Aging, Fukuroi, Japan) as
described previously.5 The detection range was 0.5200 ng/ml.
Urinary 8-OHdG excretion was expressed as the total amount
excreted in 24 h. Urinary 8-epi-PGF2a concentrations were measured
using a Urinary Isoprostane ELISA Kit (MED.DIA s.r.l., San
Germano Vercellese, Italy). The detection range was 0.0550 ng/ml.
Urinary 8-epi-PGF2a excretion was expressed as the total amount
excreted in 24 h.
Immunohistochemistry
Immunostaining for 8-OHdG in the kidney was performed as
described previously.21 Briefly, the kidneys were fixed in 10%
formaldehyde and embedded in paraffin. Paraffin sections were cut
at 3 mm and deparaffinized. After inactivation of endogenous
peroxidase with 10% H2O2 in methanol for 20 min at room
temperature, the sections were preincubated for 30 min with 1%
bovine serum albumin in phosphate-buffered saline. The samples
were then incubated with anti-8-OHdG mouse monoclonal anti-
body (4 mg/ml; Japan Institute for the Control of Aging) overnight at
41C, washed in phosphate-buffered saline, and probed with anti-
mouse IgG antibody labeled with peroxidase (Histofine Simple Stain
MAX PO(M); Nichirei, Tokyo, Japan) for 30 min at room
temperature. The peroxidase was then visualized with diaminoben-
zidine (Nichirei). The primary antibody was replaced with mouse
IgG as a negative control. To explore the mechanism underlying
increased oxidative stress in the diabetic kidney, immunostaining of
the NAD(P)H oxidase component NOX4 was performed as
described previously.21 The samples were incubated with anti-
human NOX4 goat polyclonal antibody (2mg/ml) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) overnight at 41C, washed in
phosphate-buffered saline, and probed with anti-goat IgG antibody
labeled with peroxidase (Histofine Simple Stain MAX PO(G);
Nichirei) for 30 min at room temperature. The primary antibody
was replaced with sera obtained from a goat before immunization as
a negative control. The peroxidase was then visualized with
diaminobenzidine.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from the frozen kidney samples using Isogen
(Nippon Gene, Tokyo, Japan) according to the manufacturer’s
478 Kidney International (2007) 72, 473–480
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instructions. The extracted RNA (4 mg) was converted into single-
stranded cDNA by a reverse transcriptase procedure with Super-
script II (Invitrogen, Carlsbad, CA, USA). mRNA levels were
quantified by quantitative RT-PCR using a LightCycler 2.0
instrument (Roche Diagnostics GmbH, Mannheim, Germany) as
described previously.43 Briefly, 1 ml of cDNA was placed in a 20 ml
reaction volume containing 1 ml of each primer and 2 ml of
LightCycler-FastStart DNA Master SYBR green I (Roche Diagnostics
GmbH). Nucleotide, Taq DNA polymerase, and buffer were
included in the LightCycler-FastStart DNA Master SYBR green I.
The amplification conditions comprised an initial denaturation step
at 951C for 10 min, followed by amplification of the target DNA for
40 cycles of 951C (0 s) and 601C (15 s), and extension at 721C (36 s).
Melting curve analysis was performed immediately after amplifica-
tion at a linear temperature transition rate of 0.11C/s from 651C to
951C with continuous fluorescence acquisition. The following
primer pairs were used:
NOX4, 50-ATTTGGATAGGCTCCAGGCAAAC-30 (sense) and
50-CACATGGGTATAAGCTTTGTGAGCA-30 (antisense);
TGF-b1, 50-AACAACGCCATCTATGAG-30 (sense) and 50-TATTC
CGTCTCCTTGGTT-30 (antisense);
fibronectin, 50-TGGCTGCCTTCAACTTCTCCT-30 (sense) and
50-TGTTTGATCTGGACTGGCAGTTT-30 (antisense);
b-actin, 50-TGACAGGATGCAGAAGGAGA-30 (sense) and 50-GC
TGGAAGGTGGACAGTGAG-30 (antisense).
The linearity of the amplifications as a function of the cycle
number was tested in preliminary experiments, and NOX4/TGF-b1/
fibronectin mRNA expression was normalized to expression of the
housekeeping gene b-actin. PCR products were separated on a 4%
agarose gel containing ethidium bromide.
Morphologic study
To examine the effect of pitavastatin on mesangial matrix expansion,
db/db mice, and age-matched db/þ mice were given the drug orally,
mixed in standard chow (5 mg/kg/day) for 12 weeks (from 12 to 24
weeks of age). After 12 weeks of treatment, the mice were anesthetized
and killed. The kidneys were rapidly dissected, fixed in 10%
formaldehyde, and embedded in paraffin. Paraffin sections were cut
at 3mm, perpendicular to the long axis of the kidney, for
morphometric analysis. For analysis of the glomeruli, sections were
stained with PAS. To semiquantify mesangial expansion, sections were
coded and read by an observer unaware of the experimental protocol
applied. In each animal of the four experimental groups, 30 glomeruli
were used and averaged for morphometric analysis. The extent of
increase in the mesangial matrix (defined as the mesangial area) was
determined by the presence of PAS-positive and nuclei-free areas in
the mesangium, which were traced along the outline of the capillary
loop using Scion imaging software (Scion, Frederick, MD, USA).
Statistical analysis
Data were expressed as the mean7s.e. Differences between groups
were analyzed using Student’s t-test with a two-tailed test of
significance. Multiple comparisons among the groups were con-
ducted by one-way analysis of variance with Fisher’s probable least-
squares difference test for post hoc analysis. P-values of o0.05 were
considered significant.
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